Unknown

Dataset Information

0

SARS-CoV-2 spike host cell surface exposure promoted by a COPI sorting inhibitor.


ABSTRACT: Via an insufficient coat protein complex I (COPI) retrieval signal, the majority of SARS-CoV-2 spike (S) is resident in host early secretory organelles and a tiny amount is leaked out in cell surface. Only surface-exposed S can be recognized by B cell receptor (BCR) or anti-S therapeutic monoclonal antibodies (mAbs) that is the trigger step for B cell activation after S mRNA vaccination or infected cell clearance by S mAbs. Now, a drug strategy to promote S host surface exposure is absent. Here, we first combined structural and biochemical analysis to characterize S COPI sorting signals. A potent S COPI sorting inhibitor was then invented, evidently capable of promoting S surface exposure and facilitating infected cell clearance by S antibody-dependent cellular cytotoxicity (ADCC). Importantly, with the inhibitor as a probe, we revealed Omicron BA.1 S is less cell surface exposed than prototypes because of a constellation of S folding mutations, possibly corresponding to its ER chaperone association. Our findings not only suggest COPI is a druggable target against COVID-19, but also highlight SARS-CoV-2 evolution mechanism driven by S folding and trafficking mutations.

SUBMITTER: Li Y 

PROVIDER: S-EPMC10110937 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

SARS-CoV-2 spike host cell surface exposure promoted by a COPI sorting inhibitor.

Li Yiqun Y   Yang Mingrui M   Nan Yanan Y   Wang Jiaming J   Wang Sanjiao S   Cui Dongxiao D   Guo Jiajian J   He Pengfei P   Dai Wenxin W   Zhou Shuqi S   Zhang Yue Y   Ma Wenfu W  

Acta pharmaceutica Sinica. B 20230418


<i>Via</i> an insufficient coat protein complex I (COPI) retrieval signal, the majority of SARS-CoV-2 spike (S) is resident in host early secretory organelles and a tiny amount is leaked out in cell surface. Only surface-exposed S can be recognized by B cell receptor (BCR) or anti-S therapeutic monoclonal antibodies (mAbs) that is the trigger step for B cell activation after S mRNA vaccination or infected cell clearance by S mAbs. Now, a drug strategy to promote S host surface exposure is absent  ...[more]

Similar Datasets

| EMPIAR-10947 | biostudies-other
| S-EPMC10008190 | biostudies-literature
| EMPIAR-11038 | biostudies-other
| EMPIAR-10891 | biostudies-other
| EMPIAR-10951 | biostudies-other
| EMPIAR-10952 | biostudies-other
| EMPIAR-11181 | biostudies-other
| EMPIAR-10516 | biostudies-other
| EMPIAR-10723 | biostudies-other
2023-08-31 | E-MTAB-13040 | biostudies-arrayexpress